---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060238"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:57:52.318094+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Janux Therapeutics Q3 net loss narrows to $11.6M; cash $349.7M supports operations through 2027

## Summary
- Net loss $11.6M vs $16.7M YoY; R&D expenses $11.9M, G&A $6.4M.
- Cash and short-term investments $349.7M, up from $327.0M at year-end 2022, expected to fund operations through 2027.
- Enrollment ongoing for JANX007 (PSMA-TRACTr) in prostate cancer and JANX008 (EGFR-TRACTr) in solid tumors; update expected in 2024.
- IND-enabling studies completed for JANX009 (PD-L1xCD28 TRACIr); TROP2-TRACTr candidate identified.

## SEC filing metadata
- accession: 0000950170-23-060238
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017023060238/0000950170-23-060238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017023060238/janx-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060238
- JSON: https://secwatch.observer/filing/0000950170-23-060238.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060238.txt

## Key facts
- Earnings Releases
  Janux Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $11.6 million.
  - Period: third quarter ended September 30, 2023
  - Net income: net loss of $11.6 million
  - Result: reported results
  source text: Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017023060238/0000950170-23-060238-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.